LeonaBio, Inc. Rebrands, Changes Ticker to LONA Following Transformative Acquisition and Financing
ATHA has more than doubled off its 52-week low of $2.195 on light trading volume (0.1× avg).
Summary
LeonaBio, Inc. (formerly Athira Pharma, Inc.) announced a corporate rebranding, including a name and ticker symbol change to "LONA," to reflect its recent transformative acquisition of a Phase 3 breast cancer program and significant financing.
Key Events · Corporate Governance and Compliance · ATHA
-
Corporate Rebranding
Athira Pharma, Inc. officially changed its name to LeonaBio, Inc. and will trade under the new ticker symbol "LONA" on The Nasdaq Capital Market, effective January 12, 2026.
-
Strategic Rationale
The rebranding reflects a transformative acquisition of rights to a Phase 3 program for metastatic breast cancer (lasofoxifene) and a recent $90 million financing, providing capital through 2028.
-
Executive Compensation Update
The Chief Financial Officer, Robert Renninger, received an amended change in control and severance agreement and an increase in annual base salary to $460,000.
Analysis · ATHA · Life Sciences
The company's rebranding to LeonaBio, Inc. and new ticker symbol "LONA" signals a major strategic pivot following its recent acquisition of rights to a Phase 3 metastatic breast cancer program (lasofoxifene) and a substantial $90 million financing. For a micro-cap company, this move indicates a renewed focus, a de-risked financial runway into 2028, and a commitment to advancing late-stage assets. This strategic shift, highlighted by the corporate identity change, is a significant positive development for the company's future prospects. Additionally, the CFO's severance agreement was amended, and their annual base salary was increased to $460,000, which are routine compensation adjustments.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHA was trading at $6.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.6M. The 52-week trading range was $2.20 to $8.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.